Brought to you by 
Talecris Biotherapeutics sells $600mm in senior notes
19 Oct 2009
Executive Summary
Less than two weeks after pricing its initial public offering to gross $550mm, Talecris Biotherapeutics (plasma-derived protein therapeutics for chronic and acute diseases) has raised $600mm through the sale of seven-year 7.75% senior notes--at 99.321% of par--to institutional investors. The company, which had initially planned to sell only $550mm in debt, will use the money pay back first and second lien loans and a portion of its revolving credit facility.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Nonconvertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Talecris Biotherapeutics sells $600mm in senior notes
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice